CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-09 | Musket David B Director | Purchase | +5,083 | $2.82 | $14K | 31,126 |
| 2023-10-06 | Auwaerter Paul Gisbert Director | Purchase | +5,000 | $2.84 | $14K | 5,000 |
| 2023-10-04 | Musket David B Director | Purchase | +2,500 | $2.90 | $7K | 26,043 |
| 2023-09-01 | Kelliher Mike Director | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2023-08-14 | Litvack Frank Director | Option exercise | +20,748 | $1.39 | $29K | 137,633 |
| 2023-08-14 | Litvack Frank Director | Shares withheld for taxes | −4,364 | $6.61 | $29K | 133,269 |
| 2023-08-14 | Litvack Frank Director | Option exercise · Stock Option (Right to Buy) | −20,748 | 0 | ||
| 2023-07-21 | Gotwals Philip J Director | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2023-07-11 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2023-05-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Option exercise | +20,749 | $1.39 | $29K | 198,604 |
| 2023-05-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) | −41,497 | 0 | ||
| 2023-04-17 | Avat Xavier Former CBO | Sale | −14,772 | $64,258.00 | $949.2M | 0 |
| 2023-04-05 | Avat Xavier FORMER CHIEF BUSINESS OFFICER | Option exercise | +84,791 | $3.46 | $293K | 84,791 |
| 2023-04-05 | Avat Xavier FORMER CHIEF BUSINESS OFFICER | Shares withheld for taxes | −70,019 | $4.19 | $293K | 14,772 |
| 2023-04-05 | Avat Xavier FORMER CHIEF BUSINESS OFFICER | Option exercise · Stock Option (Right to Buy) | −84,791 | 0 | ||
| 2023-03-28 | Avat Xavier FORMER CHIEF BUSINESS OFFICER | Sale | −3,000 | $4.06 | $12K | 0 |
| 2023-02-21 | Manzo Louis Director | Option exercise | +1,401 | $1.39 | $2K | 62,599 |
| 2023-02-21 | Manzo Louis Director | Returned to the company | −452 | $4.31 | $2K | 62,147 |
| 2023-02-21 | Manzo Louis Director | Option exercise · Stock Option (Right to Buy) | −1,401 | 0 | ||
| 2023-02-21 | Litvack Frank Director | Option exercise | +14,027 | $1.39 | $19K | 141,800 |
Page 9 of 24 · 468 trades